← Browse by Condition
Medical Condition
recurrent chronic myelogenous leukemia bcr abl1 positive
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT01746836 Phase 2
Recruiting
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Enrollment
50 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center